HARBIN, China, Feb. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) , a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People’s Republic of China (“PRC”), today announced that the Company’s Chief Financial Officer, Mr. Yu-bo (Stanley) Hao, will present and conduct one-on-one meetings at the upcoming Roth 21st Annual OC Growth Stock Conference in Dana Point, California.
A replay of the presentation will be available for 90 days following the live presentation using the same link and will also be available on the Company’s website.
The ROTH 21st Annual OC Growth Stock Conference will feature presentations from over 200 growth companies. This event is designed to provide investors with a unique opportunity to gain insight into leading companies across all sectors. Additionally, there will be a special track dedicated to companies based in China. Presentations will provide a brief overview of the company’s operations, and speakers will spend the majority of their time discussing topics that will highlight the value and investment opportunity their company represents.
Interested parties and investors may find more information about the conference by contacting conference@roth.com or calling (800) 933-6830.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (“TDR”), Harbin First Bio- Engineering Company Limited (“First”), Heilongjiang Tianlong Pharmaceutical, Inc. (“Tianlong”) and Peng Lai Jin Chuang Pharmaceutical Company (“Jin Chuang”) the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
CONTACT: Company Contact: Mr. Yu-Bo (Stanley) Hao, CFO of China Sky One
Medical, Inc., +86-451-5399-4069, or china_sky_one@yahoo.cn; Or Investor
Relations Contact: Mr. Crocker Coulson, President of CCG Investor
Relations, +1-646-213-1915, or crocker.coulson@ccgir.com
Web site: http://www.skyonemedical.com/
http://www.wsw.com/webcast/roth20/cski//
http://www.ccgirasia.com/
